X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (459) 459
cyclo-oxygenase-2 (327) 327
nonsteroidal antiinflammatory drugs (306) 306
index medicus (269) 269
male (257) 257
animals (249) 249
cyclo-oxygenase-2 inhibitors (239) 239
pharmacology & pharmacy (231) 231
female (203) 203
anti-inflammatory agents, non-steroidal - adverse effects (176) 176
cox-2 inhibitors (151) 151
rheumatoid-arthritis (145) 145
cyclooxygenase 2 (141) 141
celecoxib (140) 140
aged (135) 135
middle aged (131) 131
cyclooxygenase-2 (130) 130
rats (122) 122
nonsteroidal anti-inflammatory drugs (114) 114
cyclooxygenase inhibitors - pharmacology (107) 107
risk (107) 107
risk factors (107) 107
anti-inflammatory agents, non-steroidal - therapeutic use (106) 106
expression (102) 102
membrane proteins (99) 99
inflammation (95) 95
gastrointestinal toxicity (93) 93
cyclooxygenase 2 - metabolism (92) 92
adult (91) 91
selective cyclo-oxygenase-2 inhibitors (90) 90
cyclooxygenase 2 inhibitors (89) 89
cyclooxygenase 2 inhibitors - adverse effects (88) 88
dose-response relationship, drug (83) 83
osteoarthritis (83) 83
rofecoxib (83) 83
cox-2 (79) 79
mice (73) 73
biochemistry & molecular biology (71) 71
prostaglandin-endoperoxide synthases - metabolism (71) 71
cyclooxygenase (70) 70
gastroenterology & hepatology (69) 69
anti-inflammatory agents, non-steroidal - pharmacology (67) 67
cyclooxygenase 2 inhibitors - therapeutic use (64) 64
sulfonamides - pharmacology (64) 64
double-blind (62) 62
myocardial-infarction (62) 62
nsaids (62) 62
aged, 80 and over (61) 61
cyclooxygenase 2 inhibitors - pharmacology (61) 61
prostaglandins (60) 60
acute myocardial-infarction (58) 58
induction (57) 57
cyclooxygenase-2 inhibitors (56) 56
aspirin (55) 55
cyclo‐oxygenase‐2 (55) 55
isoenzymes - metabolism (55) 55
medicine, general & internal (53) 53
rheumatology (53) 53
rats, wistar (50) 50
cardiovascular diseases - chemically induced (49) 49
cyclooxygenase 1 (49) 49
cells, cultured (48) 48
gastrointestinal diseases - chemically induced (48) 48
randomized controlled-trial (48) 48
research (48) 48
pain (47) 47
cyclooxygenase inhibitors - adverse effects (46) 46
low-dose aspirin (46) 46
complications and side effects (45) 45
oncology (45) 45
anti-inflammatory agents, non-steroidal - administration & dosage (44) 44
arthritis (44) 44
cyclo-oxygenase-2 inhibitor (44) 44
cyclooxygenase-2 expression (44) 44
drug therapy (44) 44
blood-pressure (43) 43
cardiac & cardiovascular systems (43) 43
cell biology (43) 43
cyclooxygenase inhibitors - therapeutic use (43) 43
messenger-rna (43) 43
time factors (43) 43
cancer (42) 42
isoenzymes - antagonists & inhibitors (42) 42
apoptosis (41) 41
cardiovascular events (41) 41
rats, sprague-dawley (41) 41
risk assessment (41) 41
treatment outcome (41) 41
cyclooxygenase 2 - genetics (40) 40
metaanalysis (40) 40
immunohistochemistry (39) 39
medicine & public health (39) 39
nitric oxide (39) 39
nitric-oxide synthase (39) 39
cardiovascular risk (38) 38
naproxen (38) 38
care and treatment (37) 37
non-steroidal anti-inflammatory drugs (37) 37
prostaglandin-endoperoxide synthases - biosynthesis (37) 37
abridged index medicus (36) 36
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 10/2006, Volume 296, Issue 13, pp. 1633 - 1644
Context Evidence that rofecoxib increases the risk of myocardial infarction has led to scrutiny of other nonsteroidal anti-inflammatory drugs ( NSAIDs).... 
RHEUMATOID-ARTHRITIS | MEDICINE, GENERAL & INTERNAL | GENERAL-POPULATION | EVENTS | METAANALYSIS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | CYCLO-OXYGENASE-2 INHIBITORS | ROFECOXIB | CORONARY HEART-DISEASE | ASPIRIN
Journal Article
STEM CELLS, ISSN 1066-5099, 04/2015, Volume 33, Issue 4, pp. 1173 - 1186
Maximal homing of infused stem cells to diseased tissue is critical for regenerative medicine. Pulsed focused ultrasound (pFUS) is a clinically relevant... 
MDX | Mesenchymal stromal cell, Mesenchymal stem cell, Cell homing | Cytokines | Cell adhesion molecules | Tumor necrosis factor alpha | Cyclooxygenase‐2 | muscular dystrophy | Etanercept | Ibuprofen | muscle | Nuclear factor kappa‐light‐chain‐enhancer of activated B cells | Focused ultrasound | Mechanotransduction | Mesenchymal stem cell | Nuclear factor kappa-light-chain-enhancer of activated B cells | Mesenchymal stromal cell | Cell homing | Cyclooxygenase-2 | KAPPA-B ACTIVATION | HUMAN SKELETAL-MUSCLE | CELL BIOLOGY | IN-VITRO | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ECCENTRIC EXERCISE | GENE-EXPRESSION | ANGIOGENIC RESPONSE | DUCHENNE MUSCULAR-DYSTROPHY | HEMATOLOGY | STEM-CELLS | MICROBUBBLE DESTRUCTION | CELL & TISSUE ENGINEERING | ONCOLOGY | TARGETED DELIVERY | Ultrasonic Waves | Mesenchymal Stromal Cells - drug effects | Mesenchymal Stromal Cells - radiation effects | Cyclooxygenase 2 Inhibitors - pharmacology | Mechanotransduction, Cellular - drug effects | Humans | Cells, Cultured | Mice, 129 Strain | Mechanotransduction, Cellular - physiology | Muscular Dystrophies - pathology | Mice, Inbred C3H | Mice, Knockout | Young Adult | Animals | Female | Mice | Tumor Necrosis Factor-alpha - biosynthesis | Mesenchymal Stromal Cells - physiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Cyclo-oxygenase-2 | Mesenchymal Stem Cell | mechanotransduction | Cell Homing
Journal Article
Journal of Immunology, ISSN 0022-1767, 08/2004, Volume 173, Issue 3, pp. 2011 - 2022
The cyclooxygenase 2 (COX-2) inhibitor celecoxib (also called celebrex), approved,for the treatment of colon carcinogenesis, rheumatoid arthritis, and other... 
INDUCED APOPTOSIS | CHEMOPREVENTIVE ACTIVITY | CYCLIN D1 EXPRESSION | PROSTATE-CANCER CELLS | NECROSIS-FACTOR-ALPHA | INDUCIBLE PHOSPHORYLATION | IMMUNOLOGY | TRANSCRIPTION FACTOR | ANTIINFLAMMATORY DRUGS | CYCLO-OXYGENASE-2 INHIBITOR | ADENOMATOUS POLYPOSIS | Tumor Necrosis Factor-alpha - metabolism | Okadaic Acid - pharmacology | Tetradecanoylphorbol Acetate - pharmacology | Humans | Transcription Factor RelA | Lung Neoplasms - pathology | NF-kappa B - metabolism | Neoplasm Proteins - antagonists & inhibitors | Cell Line, Tumor - drug effects | I-kappa B Proteins - metabolism | Neoplasm Proteins - metabolism | Promoter Regions, Genetic - drug effects | TNF Receptor-Associated Factor 1 | TNF Receptor-Associated Factor 2 | Cyclin D1 - antagonists & inhibitors | Carcinogens - pharmacology | Protein Processing, Post-Translational - drug effects | Receptors, Tumor Necrosis Factor - antagonists & inhibitors | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Phosphorylation - drug effects | Cell Line, Tumor - metabolism | Genes, Reporter | Protein-Serine-Threonine Kinases - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | NF-KappaB Inhibitor alpha | NF-kappa B - antagonists & inhibitors | Lung Neoplasms - enzymology | Pyrazoles | Celecoxib | Enzyme Activation - drug effects | I-kappa B Kinase | Sulfonamides - pharmacology | Cyclooxygenase Inhibitors - pharmacology | Interleukin-1 - pharmacology | Proto-Oncogene Proteins c-akt | MAP Kinase Signaling System - drug effects | Lipopolysaccharides - pharmacology | Matrix Metalloproteinase Inhibitors | Carcinoma, Non-Small-Cell Lung - enzymology | Proteins - antagonists & inhibitors | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10087, pp. 2375 - 2382
Summary Background Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require... 
Internal Medicine | RHEUMATOID-ARTHRITIS | CYCLO-OXYGENASE-2 | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY | DICLOFENAC | PREVENTION | RISK | OSTEOARTHRITIS | Celecoxib - administration & dosage | Recurrence | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Secondary Prevention - methods | Aspirin - administration & dosage | Cyclooxygenase 2 Inhibitors - adverse effects | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Naproxen - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Aged, 80 and over | Aspirin - therapeutic use | Drug Therapy, Combination | Celecoxib - adverse effects | Naproxen - adverse effects | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Cyclooxygenase 2 Inhibitors - administration & dosage | Peptic Ulcer Hemorrhage - chemically induced | Celecoxib - therapeutic use | Proton Pump Inhibitors - therapeutic use | Naproxen - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Arthritis - drug therapy | Aged | Care and treatment | Aspirin | Anti-inflammatory drugs | Gastrointestinal diseases | Naproxen | Clinical trials | Arthritis | Complications and side effects | Medical research | Gastrointestinal bleeding | Medicine, Experimental | Drugs | Funding | Risk | Population studies | Hemorrhage | Evidence-based medicine | Bleeding | Incidence | Motivation | Safety | Nonsteroidal anti-inflammatory drugs | Digestive system | Risk reduction | Inflammation | Celecoxib | Patients | Anti-inflammatory agents | Diseases | Omeprazole | Random numbers | Inhibitors | Ulcers | Healing | Fatalities | Cyclooxygenase-2 | Cardiovascular diseases | Health risk assessment | Protons | Randomization | Analgesics | Endoscopy | Drug dosages | Mortality | Health risks | Hospitals
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 06/2006, Volume 113, Issue 25, pp. 2906 - 2913
Background-The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs ( NSAIDs) have been associated with... 
Drugs | Myocardial infarction | Cyclooxygenase-2 inhibitors | Mortality | Nonsteroidal antiinflammatory drugs | RHEUMATOID-ARTHRITIS | POPULATION | CARDIAC & CARDIOVASCULAR SYSTEMS | drugs | CARDIOVASCULAR EVENTS | myocardial infarction | CONVERTING ENZYME-INHIBITORS | RANDOMIZED CONTROLLED-TRIAL | CELECOXIB | BLOOD-PRESSURE | nonsteroidal antiinflammatory drugs | mortality | CYCLO-OXYGENASE-2 INHIBITORS | ROFECOXIB | PERIPHERAL VASCULAR DISEASE | BETA-BLOCKERS | HEMATOLOGY | cyclooxygenase-2 inhibitors | Ibuprofen - therapeutic use | Multivariate Analysis | Recurrence | Sulfones - therapeutic use | Confidence Intervals | Myocardial Infarction - mortality | Pyrazoles - therapeutic use | Patient Readmission | Humans | Middle Aged | Sulfones - adverse effects | Male | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Cyclooxygenase 2 Inhibitors - therapeutic use | Aged, 80 and over | Female | Registries | Retrospective Studies | Odds Ratio | Pyrazoles - adverse effects | Diclofenac - therapeutic use | Diclofenac - adverse effects | Risk Factors | Proportional Hazards Models | Celecoxib | Lactones - adverse effects | Lactones - therapeutic use | Cross-Over Studies | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Myocardial Infarction - drug therapy | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Denmark | Sulfonamides - adverse effects | Aged | Ibuprofen - adverse effects
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 4, pp. 784 - 792.e9
Journal Article
BMJ, ISSN 0959-8138, 2009, Volume 339, Issue jul14 1, pp. b2538 - b2538
Journal Article
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 11/2006, Volume 43, Issue 10, pp. 1272 - 1276
Background. Previous studies have examined the association between proton pump inhibitor (PPI) use and the risk of Clostridium difficile-associated disease... 
INFECTIOUS DISEASES | DIARRHEA | PERFORMANCE | GENERAL-PRACTICE | MICROBIOLOGY | COMORBIDITY ADJUSTMENT | IMMUNOLOGY | RISK-FACTOR | COMMUNITY | CYCLO-OXYGENASE-2 INHIBITORS | EPIDEMIC | ELDERLY-PATIENTS | STRAIN
Journal Article